1. Scrip
  2. >>Therapy Areas

FDA OK's 1st generic copycats of Otsuka's Abilify

 
• By Donna Young

Otsuka was unsuccessful in preventing the FDA from approving generic versions of the company's schizophrenia and bipolar disorder drug Abilify (aripiprazole).

Otsuka was unsuccessful in preventing the FDA from approving generic versions of the company's schizophrenia and bipolar disorder drug Abilify (aripiprazole).

The agency gave the go-ahead on 28 April to Alembic Pharmaceuticals, Hetero Labs, Teva and Torrent Pharmaceuticals to market generic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.